# Seroma and Hematoma Rates: MAXIGESIC IV vs. Ketorolac in Breast Cancer Surgery

> **NCT06575049** · — · NOT_YET_RECRUITING · sponsor: **Seoul National University Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Breast Cancer
- Post-Operative Hematoma
- Seroma as Procedural Complication
- Post-Op Complication

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06575049
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05-01
- **Primary completion:** 2025-08-30
- **Final completion:** 2026-02-20
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06575049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06575049, "Seroma and Hematoma Rates: MAXIGESIC IV vs. Ketorolac in Breast Cancer Surgery". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT06575049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*